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1. Abstract 
Purpose: Tape-stripping the stratum corneum (SC) is used in the assessment of 
dermatopharmacokinetics (DPK). The amount of SC per tape can be determined 
gravimetrically, but a novel imaging method offers advantages in terms of sensitivity, 
reproducibility, precision, stability and speed.  High-resolution images, acquired under 
controlled conditions, are analysed in terms of pixel greyscale values and distributions, 
and their usefulness in DPK studies is validated in this study using acyclovir. 
Methods: At all tape-stripped sites, the SC amount per tape was measured 
gravimetrically and by imaging. In a first series of experiments, untreated sites were 
stripped to determine total SC thickness. Subsequently, post-application of two acyclovir 
creams, drug-permeation profiles were constructed. 
Results: The greyscale values from the imaging data can be used directly to estimate 
total SC thickness and DPK parameters. The results compared favourably with the 
traditional weighing method.  The concentration of drug on each tape, as a function of 
the relative position within the SC, permitted diffusivity and partitioning parameters 
characterising the penetration of acyclovir to be derived.   
Conclusion: The new imaging approach offers a sensitive, reproducible, precise, and 
rapid technique to quantify the relative SC amount removed on tape-strips, and 
facilitates the acquisition of DPK data.  
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2. Abbreviations 
 
ACV  Acyclovir 
ANGi Absolute normalised SC greyscale on tape i 
ANTi Absolute normalised SC thickness on tape i 
B Baseline correction factor for non-linear model using cumulative thickness 
Bg Baseline correction factor for non-linear model using cumulative greyscale 
Cg 
Drug concentration at depth, g, within SC, as measured by cumulative integrated 
pixel density 
Cmax Maximum drug concentration achieved in SC 
CV Coefficient of variation 
Cv Drug concentration in the vehicle 
Cx Drug concentration at depth, x, within SC, as measured gravimetrically 
Dw Diffusivity of water in SC 
D/H2 Drug’s diffusivity parameter in SC 
DPK Dermatopharmacokinetics 
G Total SC thickness, estimated by greyscale integrated pixel density 
G Cumulative integrated pixel density of SC removed by tape stripping  
g/G 
Relative depth reached within SC, measured by integrated pixel density of SC per 
tape 
H Cumulative thickness of SC removed by tape stripping 
H Total SC thickness, estimated gravimetrically 
h/H Relative depth reached within the SC, measured gravimetrically 
KSC/VE SC-viable epidermis partition coefficient of water 
Kg 
SC-vehicle partition coefficient of drug, determined from drug concentration 
measured by cumulative integrated pixel density 
Km 
SC-vehicle partition coefficient of drug, determined from drug concentration 
measured gravimetrically 
kp Permeability coefficient of drug through SC 
Rg Average concentration of drug in SC quantified by greyscale integrated pixel density 
Rm Average concentration of drug in SC quantified gravimetrically 
rs Spearman’s correlation coefficient (non-parametric correlation) 
SC  Stratum corneum 
SER Standard error of regression 
TEWL Transepidermal water loss 
TEWL0 Initial TEWL measured before tape stripping 
ΔCw Concentration gradient of water across the SC 
 
3. Introduction 
Dermatopharmacokinetics (DPK) permits the rate and extent of drug permeation 
through the skin to be determined by analyzing the active compound in stratum 
corneum (SC) layers, which are progressively removed by tape-stripping [1-11]. When 
the drug concentration on each tape is determined individually, penetration profiles 
may be derived, as a function of depth within the SC (and, to facilitate comparison 
between the results of different experiments, these depths are expressed relative to the 
total SC thickness, which is measured separately).  
The drug concentration profiles can be fitted to an appropriate solution of Fick’s second 
law of diffusion, to derive the SC-vehicle partition coefficient and a measure of the drug’s 
diffusivity in the SC [12-20].  These parameters may then be compared for different 
formulations [14,17,19,20]. The amount of SC on each tape is required (a) to express the 
drug mass measured per tape as a concentration (in terms of a SC ‘volume’); (b) to 
measure the depth reached within the SC; and (c) to measure, at a separate site, the total 
SC thickness so that the depth reached may be expressed relative to this value at each 
site tested in each subject.  
Traditionally, weighing tapes before and after stripping has been used to estimate the 
mass of SC removed per tape [1].  The latter is then converted to SC thickness using the 
known the area and SC density (~1 g/cm3 [21]). At an adjacent, untreated site, stripping 
is performed with concomitant TEWL measurements, to derive an estimate for the total 
SC thickness [22,23].  
Recently [24], a novel imaging method has been developed to quantify SC on tape-strips 
and shown to be more precise and sensitive than the gravimetric approach, with a 
higher signal-to-noise ratio. A high-resolution image of each tape is acquired under 
controlled lighting conditions, and the individual pixels provide an associated greyscale 
value, which may be measured and analysed.  The mean greyscale value per tape 
multiplied by the strip area provides a relative measure (the integrated pixel density) of 
SC on the tape.  
In this paper, an initial series of experiments determined cumulative integrated pixel 
densities (g) and, with concomitant transepidermal water loss (TEWL) measurements, 
were input directly into a non-linear model [23] to estimate total SC thickness (G) in 
human volunteers. Subsequently, the cumulative integrated pixel density on each tape 
strip was used to validate (and provide proof-of-concept for) the greyscale measure of 
SC amount per tape to derive dermatopharmacokinetic profiles for two topical acyclovir 
(ACV) cream formulations.  
 
4. Materials and Methods 
An initial set of experiments was performed to determine whether greyscale values 
could be used to estimate total SC thickness; comparisons were made with gravimetric 
measurements. Subsequently, a proof-of-concept study examined the use of greyscale 
values in existing dermatopharmacokinetic models to compare two acyclovir 
formulations; validation of the approach involved parallel assessment of concentration 
profiles with the traditional gravimetric technique for SC quantification.  
4.1 Subjects 
Healthy volunteers, with no history of dermatological disease, participated in the study. 
Ethical approval was granted by the Salisbury Local Research Ethics Committee; the 
Declaration of Helsinki protocols were followed, and written informed consent was 
obtained from all volunteers. Participants refrained from using any topical products on 
the test area on the day of the experiments.  
4.2 Tape stripping 
2 x 3 cm2 tapes were cut from Scotch Book tape 845 (3M, St. Paul, MN) and stored 
overnight in covered trays.  
Prior to any tape stripping experiment, two light “pre-tapes” were applied and 
discarded. A plastic template was used to delimit a constant area of skin (1.5 x 1.5 cm2). 
This template had an outline marked on its underside of 2 x 3 cm2 to ensure that the 
tapes were always placed in the same position.  
Initial transepidermal water loss (TEWL) measurements were taken, until stable, with a 
closed-chamber evaporimeter (Biox Aquaflux AF102, Biox Systems, Ltd., London, UK; 
probe applied for at least 60 s, TEWL was recorded once the mean of 10 successive 
measurements had a CV < 1%). A pre-weighed tape (see below) (2 x 3 cm2) was 
positioned over the template. Adhesion was ensured with six passes over the tape with a 
weighted roller before swift removal. TEWL was re-measured. This sequence of tape 
strip and TEWL measurement was continued until the rate of water loss had increased 
to 4-5 times the control, pre-stripping value.  
4.3 Techniques to quantify SC on tape strips 
The SC amount on each tape was determined by both gravimetric and imaging methods.  
4.3.1 Weighing method 
Tapes were cut and stored (covered) for 12 hours in ambient conditions. Each blank 
tape was discharged of static electricity (R50 discharging bar with ES50 power supply 
from Eltex Electrostatik GmbH, Weil am Rhein, Germany), weighed on a microbalance 
(SE-2F, precision 0.1μg; Sartorius AG, Goettingen, Germany) and then stored (maximum 
24 hours) before being used for tape stripping. Following tape stripping, all tapes were 
again discharged of static electricity and reweighed. The mass difference between the 
two allowed the mass of SC on each tape to be calculated.  
To correct for any variations in environmental conditions, and the change in mass that 
may occur over time, 3-5 blank tapes were weighed at the same time as those used for 
stripping. The change in mass of these blank tapes was used to correct the calculated 
mass of SC on each tape used in the experiments.  
Knowing the mass of SC on the tape, the area, and the density of SC (~1 g/cm3) [21], the 
thickness of SC on each tape could be calculated, and hence the cumulative SC thickness 
removed derived. 
4.3.2 Imaging method 
The procedure followed the steps outlined above but, after the second weighing, the 
tapes were mounted onto slides before being photographed under controlled lighting 
conditions using a Coolscan V ED (Nikon UK Limited, Kingston upon Thames, UK) slide 
scanner. Image resolution was 4000 pixels per inch. The scanner was set to positive scan 
in the greyscale colour space of 14-bit depth, with no transformations or camera 
adjustments.  
Cropped images, 2213 x 2203 pixels (approximately 1.4 x 1.4 cm2; 9822 KB each) were 
taken and then analysed with ImageJ (Rasband, W.S., U. S. National Institutes of Health, 
Bethesda, Maryland, USA; freeware from http://rsb.info.nih.gov/ij/).  A scale of 159.07 
pixels/mm was applied by measuring the full length of one side of the image. During 
image analysis, the 16-bit greyscale value of each of the 4875239 pixels in the image is 
found, in the range from 0 (black) to 64608 (white). The mean corrected greyscale value 
across all pixels was derived by subtracting from the mean greyscale value for a blank 
tape (64355); hence, large corrected mean greyscale values correspond to dark images, 
and more stratum corneum. The mean greyscale value of each tape was multiplied by 
the tape strip area (195 mm2 for all tapes in this study) to derive the integrated pixel 
density, a relative measure of SC per tape. 
4.4 Modeling and statistics 
All non-linear modeling was performed in WinNonLin® (software version 5.1, Pharsight 
Corporation, Mountain View, CA) using ASCII user-defined models. In all cases, no data 
points were excluded, uniform weighting was applied, and no bounds were used. 
All statistical tests were performed, and graphs produced, with GraphPad Prism® 
(version 4.00 for Windows, GraphPad Software, San Diego, CA). 
4.5 Initial experiments to estimate total SC thickness 
4.5.1 Subjects 
A total of 25 sites from eight volunteers (2 male, 6 female, age range 23-37 years) were 
examined over a period of 14 months.  The experiment generated a total of 388 tape 
strips, a variable number of which was obtained at each site, as the criterion for 
terminating the tape-stripping process was that TEWL had reached 4-5 times the initial 
value for that site. Repeat participation using the same arm was treated as a separate 
measurement and was delayed by at least 1 month, which is sufficient for barrier 
regeneration [25-27].  
4.5.2 Non-linear modeling 
To determine the SC thickness of each volunteer, tape stripping was performed on an 
untreated site with TEWL measurements taken before and after each tape strip. The 
sequence was repeated until the TEWL value was 4-5 times its initial value (i.e., usually 
60-80 g.m-2h-1). As mentioned before, the SC amount on each tape was determined by 
both gravimetric and imaging methods.  
The total SC thickness, H or G, was estimated from the baseline-corrected non-linear 
model [23] using either the SC thickness (Equation 1) or integrated pixel densities 
(Equation 2), respectively: 
TEWL= B+
KSC/VE ×Dw ×DC
H -h        Equation 1
 
TEWL= Bg +
(KSC/VE ×Dw ×DC)g
G- g       Equation 2
 
In Equation 1, the thickness of the SC removed (h), is determined gravimetrically. The 
change in TEWL as a function of thickness of SC stripped is fitted to the equation to 
obtain values of (a) the SC thickness (H), (b) the product of the SC-viable epidermal 
partition coefficient of water (KSC/VE), its diffusivity in the barrier (Dw), and the 
concentration gradient (ΔC) of water across the membrane, and (c) the baseline 
correction factor (B). 
In Equation 2, the SC removed by each strip is assessed by the imaging method. The 
cumulative integrated pixel density (g) for each tape is used in this expression to yield 
the total SC thickness (G) and, once again, values for Dw∙KSC/VE∙ΔC and B. Values derived 
from this model are denoted with subscript ‘g’.  
To compare easily whether the plots of TEWL against either cumulative thickness or 
cumulative integrated pixel density, and the resultant fits to Equation 1 or Equation 2, 
respectively, are equivalent, the profiles were normalised by dividing each individual 
cumulative value by the total SC thickness (H or G respectively). The following 
mathematically equivalent models are thereby deduced from Equations 1 and 2, 
respectively: 
TEWL= B+
(KSC/VE ×Dw ×DC) /H
1-h
H
      Equation 3
 
TEWL= Bg +
(KSC/VE ×Dw ×DC)g /G
1- g
G
      Equation 4
 
In the same way, total SC thickness was determined for the sites used in the formulation 
DPK study to normalize the concentration profiles obtained in the different volunteers. 
h/H with g/G values from a particular site are cumulative, and thus co-dependent. To 
assess whether the gravimetric and imaging methods produce comparable values for 
each tape individually, the absolute normalised SC thickness on tape i (ANTi) and the 
absolute normalised integrated pixel density determined for tape i (ANGi) were 
calculated with Equations 5 and 6, respectively: 
ANTi = (h H)i - (h H)i-1       Equation 5 
ANGi = (g G)i - (g G)i-1       Equation 6 
4.6 Determination of drug concentration profiles 
4.6.1 Subjects and formulations 
Two healthy female volunteers (both 30 years old), with no history of dermatological 
disease, participated in this study.  
The DPK of two 5% w/w acyclovir cream formulations, Zovirax (GlaxoSmithKline plc, 
Brentford, UK), and a generic product (Pliva Pharma, Ltd, Petersfield, UK), were 
compared. Five skin sites were examined for each volunteer: 2 sites for each of the two 
formulations, and one site at which SC thickness was determined.  
400 μL (HandyStep® volume dispenser, Brand GMBH & Co. KG, Wertheim Germany) of 
each formulation was spread over a demarcated area (2 x 2 cm2, foam template, 
No.1772, 3M United Kingdom PLC, Bracknell, UK), covered with plastic to provide 
occlusive conditions and left in place for 30 minutes. This corresponds to an infinite 
dose, chosen such that (i) no significant  depletion of drug occurs over the course of the 
experiment, and (ii) the DPK models based on Fick’s 2nd law apply. At the end of the 
application, the site was carefully cleaned with 3 wipes each of a dry tissue, and an 
alcohol wipe (Klercide, Shield Medicare Ltd, Farnham, UK), and allowed to dry for 5 
minutes.  This cleaning procedure was considered sufficient to remove any excess 
formulation, which would otherwise lead to an artificially large concentration of 
acyclovir being detected in initial tape strips.  A plastic template delimiting an area of 1.5 
x 1.5 cm2 was centered over the application area and tape stripping was performed. 
4.6.2 Acyclovir extraction and analysis 
After tape stripping, the amount of SC per tape was measured by gravimetric and 
imaging methods (see above). Subsequently, tapes were cut from the slide holders, and 
extracted overnight in 1ml of distilled water (recoveries ≥ 95%). Samples were filtered 
(Chronus® 0.45μm nylon filters, SMI-LabHut Ltd, Maisemore, UK) before HPLC analysis 
(PG80 pump, ASI-100 autosampler, TCC-100 column oven, PDA-100 UV lamp from 
Dionex Corporation Sunnyvale, California, USA) using a 15 cm Acclaim 120 column (C18, 
5 μm, 120Å) at 25°C and a mobile phase of (by volume) 0.5% acetic acid, 5% methanol, 
and 94.5% water (pH 2.97) running at 1mL/min.  The drug was detected at 254 nm; no 
interference with formulation excipients or skin was observed.  The LOQ and LOD of the 
assay were 0.049 ± 0.004 and 0.016 ± 0.001 μg/mL, respectively. 
A linear calibration curve was derived using standard solutions of acyclovir (Sequoia 
Research Products Ltd., Pangbourne, United Kingdom) in distilled water, over the 
concentration range 0.024-1.96 μg/mL. 
4.6.3 Dermatopharmacokinetic profiles 
Two concentration profiles were constructed; one based on SC depth determined 
gravimetrically the other according to the integrated pixel density.  
For the ‘mass-derived’ concentration profiles, the concentration of drug at a particular 
depth (Cx) can be expressed in terms of ACV mass per mass of SC on the tape; however, 
when the SC is quantified by imaging, the ACV mass is divided by the corresponding 
mean greyscale value, expressed as Cg. To allow the two approaches to be directly 
compared, therefore, a normalisation procedure is required and this is achieved by 
dividing the two sets of concentration data, respectively, by the average concentration of 
drug in the SC as determined by mass (Rm) and the average concentration of drug in the 
SC as determined by imaging (Rg) using Equations 7 and 8. Estimates of the average 
concentration of drug in the SC can also be found from the area under the concentration 
profiles: 
Rm =
Total ACV mass from all tapes (mg)
Total SC mass from all tapes (mg)
» Cx
0
1
ò d(h H )
   Equation 7 
Rg =
Total ACV mass from all tapes (mg)
Total SC mean greyscale value from all tapes
» Cx
0
1
ò d(g G)
  Equation 8
 
The normalised concentration of drug (Cx/Rm or Cg/Rg), as a function of time (t) and of 
position (h or g) in the SC of total thickness (H or G), may be expressed by the following 
solutions of Fick’s 2nd law of diffusion:  
Cx
Rm
=
Km
Rm
×Cv[(1-h H )-
2
p
1
n
sin(np × h H)exp(-n
2 ×p 2 × (D H 2 ) × t)
n=1
10
å ]  Equation 9 
Cg
Rg
=
Kg
Rg
×Cv[(1- g G)-
2
p
1
n
sin(np × gG)exp(-n
2 ×p 2 × (D H 2 ) × t)
n=1
10
å ]  Equation 10 
where Cv is the drug concentration in the vehicle. Two key DPK parameters may be 
estimated by fitting the experimental data to Equations 9 and 10: specifically, (i) a 
normalised estimate of the drug’s SC-vehicle partition coefficient (Km/Rm or Kg/Rg for 
the mass and greyscale measurements, respectively), and (ii) its characteristic diffusion 
parameter through the SC (D/H2, which has units of a 1st-order rate constant, [time]-1). 
Equations 9 and 10 require the following boundary conditions: (a) that an infinite dose 
is applied; (b) that the SC is initially drug-free; (c) that the barrier is homogeneous in its 
properties; and (d) that the viable epidermis provides a perfect sink for permeating 
drug. 
5. Results 
5.1 Estimating total SC thickness  
For each tape stripping site, two estimates of total SC thickness, H and G, were 
determined, respectively, from the change in TEWL as a function of (a) the cumulative 
thickness of SC (measured gravimetrically and fitted to Equation 1), and (b) the 
cumulative greyscale value (measured by the imaging method and fitted to Equation 2). 
Representative data and the corresponding fits of the non-linear models for one subject 
are shown in Figures 1A and 1B.  
Figure 2 shows the significant correlation between the H and G estimates over the 25 
sites investigated (p<0.0001, 2-tailed Gaussian approximation, Spearman correlation 
coefficient, rs = 0.80). SC thicknesses measured with the gravimetric method varied from 
8.9 to 22.6 μm, with a mean (±standard deviation) of 13.6 (± 4.0) μm, a value in good 
agreement with previous findings [13].  
The normalised values of (Dw∙KSC/VE∙ΔC/H) and (Dw∙KSC/VE∙ΔC)g/G) over all 25 data sets 
were remarkably similar: 7.38 (± 2.27) and 7.47 (± 2.49), respectively (Figure 3), and 
significantly (and positively) correlated: α = 0.05, Spearman correlation coefficient = 
0.93.  
Before any stripping begins, h and g are zero, and Equations 1 and 2 predict linear 
relationships between [TEWL0 − Dw∙KSC/VE·ΔC/H] and B, and between [TEWL0 – 
(Dw∙KSC/VE·ΔC)g/G] and Bg, respectively.  The resulting Spearman correlation coefficients 
of 0.91 and 0.94 confirm that the non-linear models fit the data well. 
5.1.1 Intra-subject variability 
Typically, when using tape-stripping to evaluate bioequivalence between topical 
formulations, SC thickness is determined at one skin site to normalise the DPK data 
obtained at adjacent sites [1]. This approach assumes, of course, that SC thickness is 
similar, on the whole, across the ventral forearm. To validate this hypothesis, the SC 
thickness of 4 volunteers on 3-5 adjacent skin sites, on the same arm, on the same day, 
was determined using results from both gravimetric (Equation 1) and imaging 
(Equation 2) experiments (Table 1).  
Comparing the relative standard deviation (RSD) values for the two models, in Subjects 
1, 2 and 4, the estimate for G has a lower RSD than the corresponding H estimate. It is 
also interesting to note that the G estimates from the different sites always had a RSD 
<10%, whereas the H estimates for Subjects 1, 2 and 4 have RSD >10%. These data 
suggest that the G estimate of SC thickness (from Equation 2) is less variable than that 
for H (from Equation 1).  
5.1.2 Comparison of normalised profiles 
To facilitate comparison of the data from the the gravimetric and imaging methods, the 
cumulative thickness values were divided by H (yielding h/H values), and the 
cumulative integrated pixel densities were divided by G (producing g/G values), as 
explained above. The results and the fits may then be superimposed (see Figure 1C).   
While the absolute SC thickness (expressed as either H or G) is useful to know, its value 
in DPK studies resides in the fact that it permits the normalisation of all data (from 
different subjects, obtained at different times), in terms of h/H or g/G, and enables 
direct comparison of different formulations and their equivalence (or not) to be 
established.  
Figure 4 presents the h/H and g/G values determined for 388 tapes. These 
measurements are significantly (p<0.0001) and positively correlated (Spearman 
correlation coefficient (rs) = 0.99). This result strongly supports the interchangeability 
of h/H and g/G values and that the imaging method may be confidently used to 
determine the relative position reached within the SC in DPK studies.  
As the h/H and g/G values are cumulative and not independent, Equations 5 and 6 were 
used to calculate, for each tape (i) respectively, the absolute normalised thickness 
(ANTi,) and absolute normalised integrated pixel density (ANGi,); the results are in 
Figure 5. There was no statistical difference between ANTi and ANGi values (paired 2-tail 
T-test, p = 0.98), although the more extreme values of ANTi, and their greater standard 
deviation (0.019 versus 0.015 for ANGi), are consistent with the better precision of the 
imaging method as recently reported [14].  Further, the narrower spread of the ANGi 
values (0.041 – 0.072; average = 0.057 ± 0.015), compared to that of ANTi (0.038 – 
0.075; average = 0.057 ± 0.019), suggests that the imaging approach may have a higher 
sensitivity to distinguish between the subtly different amounts of SC on the tape-strips. 
5.2 Estimation of drug concentration profiles 
Subsequently, in a brief, proof-of-concept study, two acyclovir creams were compared. 
SC quantities on all tape-strips from each application site were assessed both 
gravimetrically and by the imaging method.  Two drug-permeation profiles were 
thereby produced, allowing differences (a) between the gravimetric and imaging 
profiles, and (b) between the acyclovir formulations, to be considered as shown in 
Figures 7 and 8. To facilitate the comparisons, the ‘normalised concentration of drug in 
the SC’ was calculated, using Equations 7 and 8. 
The resulting DPK data from the skin sites treated with the Zovirax and Pliva creams are 
shown in Figures 7 and 8, respectively, and the normalised profiles generally overlap 
rather well.  This means that measurements derived from the imaging method provide a 
perfectly usable relative assessment of the performance of the two topical products, 
with no need for explicit knowledge of the absolute depth of drug penetration into the 
SC*.  
                                                        
* It should be noted, however, that application of Pliva cream to site 2 of Subject 5 caused significant SC 
disruption, resulting in visible ‘clumps’ of the barrier being removed, and a resulting high concentration of 
drug, on certain tape-strips (see, for instance, the result for tape 3 from this site in Figure 7B).  It was not 
possible, therefore, to further analyse this profile. 
The normalised concentration profiles were fitted to Equations 9 and 10 and the ACV 
diffusivity parameter in the SC (D/H2), and the normalised partition coefficients (Km/Rm 
and Kg/Rg, respectively), were determined (Table 2). As may be anticipated from the 
superposition of the drug permeation profiles in Figures 7 and 8, there was no 
significant difference between the results derived from the gravimetric and imaging 
approaches (2-tail paired non-parametric t-test, p>0.05).  
Estimations of the average ACV concentrations in the SC, Rm (Equation 7) and Rg 
(Equation 8) are also presented in Table 2. The latter allows Kg/Rg to be converted into a 
true vehicle-SC partition coefficient, Km. Notably, this will permit future DPK evaluations 
of formulations undertaken with the imaging method to be directly compared with 
previously studied products, for which the SC per tape was measured gravimetrically.  
The SC-vehicle partition coefficient values for Zovirax were largely reproducible, with 
Km varying between 3.7 and 6.4, and Kg from 3.1 x 10-5 to 9.5 x 10-5 over the four sites. 
The D/H2 values were consistently between 0.02 and 0.04 h-1 for both SC quantification 
methods. The higher D/H2 value observed for Subject 5 at Zovirax site 1 (Table 2) is due 
to a ‘spike’ in the ACV concentration at h/H or g/G ~0.6 (see Figure 6A) and is most 
likely due to an unexplained contamination.  
 
6. Discussion 
In the first series of experiments reported here, SC on tapes from 25 untreated skin sites 
was quantified gravimetrically and with a novel imaging method. The former approach 
is well established in DPK studies [12-20] and, when used in conjunction with 
measurements of TEWL, the total SC thickness may be estimated [23]. The latter 
technique, which is based on the determination of cumulative greyscale values of 
successive tapes [24], has also been demonstrated to provide an assessment of SC 
thickness that correlates well with the gravimetric method.  Furthermore, the intra-
subject variability associated with results from the imaging technique was found to be 
smaller due, it is believed, to the improved signal-to-noise ratio of the approach. 
The interpretation of drug concentration profiles across the skin [12-20] has been 
facilitated by analyzing the data as a function of the normalised depth of penetration into 
the barrier (as expressed in this paper by h/H).  This permits results from different 
subjects with different absolute SC thicknesses to be objectively compared.  The data 
derived for the imaging evaluation of SC amounts removed per tape-strip can also 
provide corresponding, normalised quantification of relative position within the 
membrane (described by g/G in this work).  The correlation between h/H and g/G (and 
that between Dw∙KSC/VE·ΔC/H and (Dw∙KSC/VE·ΔC)g/G) is shown to be excellent, meaning 
that the normalised SC position derived from imaging can be used in place of that 
obtained from the much more labour-intensive gravimetric approach.  The advantage of 
the greyscale method, relative to the established procedure, is further reinforced by its 
overall better precision (fewer outliers) and sensitivity (wider dynamic range) reflected 
in the absolute normalised SC amount per tape. 
A proof-of-concept DPK study was then undertaken to test whether the imaging method 
for SC quantification could be used in the comparison of two topical formulations of 
acyclovir.  SC amounts per tape-strip were also determined gravimetrically to provide 
validation of the imaging approach.  It was first established that normalisation of the 
penetration depth (by h/H or g/G) led to superimposable acyclovir concentration 
profiles across the SC.  Equally, when these profiles were fitted to the appropriate 
solutions of Fick’s 2nd law of diffusion, there were no significant differences in the 
derived diffusion and partitioning parameters.  It follows that further assessment of DPK 
characteristics using the imaging technique will be comparable with previous results 
obtained from gravimetric measurement of SC position. 
The derived partition coefficients determined in this investigation for acyclovir are 
mostly within an order of magnitude of those reported in the literature [13,16,17,19] for 
other drugs of markedly different physicochemical properties. These observations imply 
that the drug concentration in the SC at the surface of the barrier is approximately equal 
to that in the vehicle. One interpretation for this (apparent) coincidence is that residual 
formulation remains on the skin surface, or in the skin furrows [15], after the skin has 
been cleaned and before tape stripping commences. Alternatively, it may be 
hypothesised that the drug, and key formulation excipients in which the drug is soluble, 
enter the SC as a “unit”, and only separate from one another deeper within the barrier. 
There is some evidence for this idea in recent publications [18,28]: first, the uptake of 
ibuprofen into the SC from vehicles, in which the drug is present at the same (maximum) 
thermodynamic activity, is not constant but rather increases with the percentage of 
cosolvent (propylene glycol) in the formulation [18]; second, the more rapid, 
subsequent diffusion of propylene glycol, relative to ibuprofen, through the SC 
significantly impacts on drug clearance from the barrier [28] and has led its 
precipitation being observed in the surface layers [29] as the local concentration 
increases above the solubility. It follows that the assessment of bioequivalence between 
formulations must also consider carefully the potential impact of differences in the 
nature and quantity of the excipients present.   As a sensible starting point, for example, 
one might explore the use of the new imaging tools now being used in DPK studies 
[24,29] to examine acyclovir formulations, which have been shown in earlier research to 
be clearly bio-inequivalent [30]. 
 
 
7. Conclusions 
The mean cumulative greyscale values, derived from the imaging method, may be used 
instead of cumulative thickness estimates derived from the gravimetric approach (a) to 
provide direct measurement of the relative depth reached within the SC with each tape, 
(b) to estimate total SC thickness, and (c) to evaluate DPK parameters.  The cumulative 
greyscale values are generally more precise and sensitive, and have less intra-subject 
variability. In addition, the imaging method is faster and simpler, has a higher signal-to-
noise ratio, makes use of all the SC collected on a tape-strip and provides a permanent, 
digital record of the tape’s image [24]. Overall, therefore, the imaging method represents 
an experimental strategy with the potential to further enhance the value of SC tape 
stripping as a valid and informative approach for the assessment of bioequivalence 
between topical medicines.  
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9. Figure legends 
Figure 1: Representative TEWL measurements as a function of cumulative thickness 
and cumulative integrated pixel density values for one subject.   A. TEWL vs. 
cumulative thickness of SC removed (experimental data points (●) and fit to 
Equation 1 (▬)); estimated H = 12.0 μm.  B. TEWL vs. cumulative 
integrated pixel density of SC removed (experimental data points (□) and fit 
to Equation 2 (▬)); estimated G = 2.2 x 107.  C. Superimposed, normalised 
profiles: (a) TEWL vs. normalised cumulative thickness, h/H (●) and the 
resultant fit to Equation  (▬); (b) TEWL vs. normalised cumulative 
integrated pixel density, g/G (□) and the resultant fit to Equation 4 (▬).  
Figure 2: Correlation between the SC thickness estimates, H and G, with their 
respective standard errors of the regression (SER), for 25 experimental 
sites. Correlation is significant (p<0.0001) with a 2-tailed Gaussian 
approximation; Spearman correlation coefficient, rs = 0.80. 
Figure 3: Comparison of the (normalised) Dw∙KSC/VE·ΔC/H and (Dw∙KSC/VE·ΔC)g/G 
estimates (with their respective SER) for 25 different sites; a significant 
correlation (α = 0.05) is found with a 2-tail non-parametric test (p<0.0001, 
rs = 0.93). 
Figure 4: Correlation between the h/H and g/G values determined from tape-
stripping 25 skin sites (n = 388 tape-strips collected from 8 volunteers). 
The correlation (2-tail) is significant (p<0.0001), with rs = 0.99. 
Figure 5: Absolute normalised thickness (ANTi, ■, Equation 5) and absolute 
normalised integrated pixel density (ANGi, ▼, Equation 6) values for each 
tape, i (n = 388); no significant difference between the ANT and ANG values 
(paired 2-tail t-test (p = 0.98; pairing was effective (p<0.0001)). Means (●) 
and standard deviations are also presented for each method. 
Figure 6: DPK profiles of acyclovir after application of Zovirax cream.  The 
normalised concentrations on the y-axes were determined using Equations 
7 and 8, respectively, for SC amounts per tape determined either 
gravimetrically (□) or by the imaging method ().  Fitting the data to 
Equations 9 (▬) and 10 (▬) is also shown.  Graphs A and B: Subject 5, sites 
1 and 2, respectively. Graphs C and D: Subject 6, sites 1 and 2, respectively. 
Figure 7: DPK profiles of acyclovir after application of Pliva cream.  The normalised 
concentrations on the y-axes were determined using Equations 7 and 8, 
respectively, for SC amounts per tape determined either gravimetrically (□) 
or by the imaging method ().  Fitting the data to Equations 9 (▬) and 10 
(▬) is also shown.  Graphs A: Subject 5, site 1. Graphs C and D: Subject 6, 
sites 1 and 2, respectively. Graph B: Subject 5, site 2 shown for information 
only; evidence of SC disruption by Pliva cream at this site, with clumps of SC 
removed on tapes, resulting in high concentration of drug in SC on tape 3.  
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Figure 1: Representative TEWL measurements as a function of cumulative thickness and 
cumulative integrated pixel density values for one subject.   A. TEWL vs. cumulative 
thickness of SC removed (experimental data points (●) and fit to Equation 1 (▬)); 
estimated H = 12.0 μm.  B. TEWL vs. cumulative integrated pixel density of SC 
removed (experimental data points (□) and fit to Equation 2 (▬)); estimated G = 2.2 
x 107.  C. Superimposed, normalised profiles: (a) TEWL vs. normalised cumulative 
thickness, h/H (●) and the resultant fit to Equation 3  (▬); (b) TEWL vs. normalised 
cumulative integrated pixel density, g/G (□) and the resultant fit to Equation 4 (▬).  
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Figure 2: Correlation between the SC thickness estimates, H and G, with their respective 
standard errors of the regression (SER), for 25 experimental sites. Correlation is 
significant (p<0.0001) with a 2-tailed Gaussian approximation; Spearman 
correlation coefficient, rs = 0.80. 
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Figure 3: Comparison of the (normalised) Dw∙KSC/VE·ΔC/H and (Dw∙KSC/VE·ΔC)g/G estimates 
(with their respective SER) for 25 different sites; a significant correlation (α = 0.05) 
is found with a 2-tail non-parametric test (p<0.0001, rs = 0.93).  
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Figure 4: Correlation between the h/H and g/G values determined from tape-stripping 25 
skin sites (n = 388). The correlation (2-tail) is significant (p<0.0001), with rs = 0.99. 
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Figure 5: Absolute normalised thickness (ANTi, ■, Equation 5) and absolute normalised 
integrated pixel density (ANGi, ▼, Equation 6) values for each tape, i (n=388); no 
significant difference between the ANT and ANG values (paired 2-tail t-test (p = 
0.98; pairing was effective (p<0.0001)). Means (●) and standard deviations are also 
presented for each method. 
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Figure 6: DPK profiles of acyclovir after application of Zovirax cream.  The normalised 
concentrations on the y-axes were determined using Equations 7 and 8, 
respectively, for SC amounts per tape determined either gravimetrically (□) or by 
the imaging method ().  Fitting the data to Equations 9 (▬) and 10 (▬) is also 
shown.  Graphs A and B: Subject 5, sites 1 and 2, respectively. Graphs C and D: 
Subject 6, sites 1 and 2, respectively.   
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 Figure 7: DPK profiles of acyclovir after application of Pliva cream.  The normalised 
concentrations on the y-axes were determined using Equations 7 and 8, 
respectively, for SC amounts per tape determined either gravimetrically (□) or by 
the imaging method ().  Fitting the data to Equations 9 (▬) and 10 (▬) is also 
shown.  Graph A: Subject 5, site 1. Graphs C and D: Subject 6, sites 1 and 2, 
respectively. [Graph B: Subject 5, site 2 shown for information only; evidence of SC 
disruption by Pliva cream at this site, with clumps of SC removed on tapes, resulting 
in high concentration of drug in SC on tape 3.] 
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Table 1: inter-subject variability in H and G when multiple sites were examined on the same arm on the same day. 
 
  Subject 1 (n = 4)  Subject 2 (n = 3)  Subject 3 (n = 4)  Subject 4 (n = 5) 
  H (μm) 10-7 x G   H (μm) 10-7 x G  H (μm) 10-7 x G  H (μm) 10-7 x G 
Average 10.8 4.2   19.2 6.6   10.0 3.7   16.1 5.5 
SD 1.3 0.2  3.0 0.6  0.5 0.3  2.9 0.5 
RSD (%) 11.6 5.6   15.6 9.4   4.7 9.0   18.1 8.8 
 
 
Table 2:  Estimates (± standard error) of K and D/H2 from Fick’s 2nd law, for Zovirax and Pliva formulations, with SC measured using 
gravimetric and imaging techniques (Equations 9 and 10, respectively). 
 
 
Subject Site  Rm (1) 105 x 
Rg(1) 
Normalised data 
Km/Rm (2) (3)            Kg/Rg (2) (3) 
 (D/H2)mass     
(h-1) (2) (3) 
(D/H2)greyscale 
(h-1) (2) (3) 
Km 105 x Kg 
5 Zov. 1 1.6 1.0 2.4 ± 0.3 4.9 ± 0.7  0.24 ± 0.09 0.03 ± 0.01 3.7 ± 0.5 4.7 ± 0.6 
 Zov. 2  0.9 0.5 4.8 ± 0.4 6.0 ± 0.3  0.03 ± 0.01 0.02 ± 0.00 4.1 ± 0.3 3.1 ± 0.2 
6 Zov. 1 1.6 1.3 4.0 ± 0.4 7.1 ± 0.5  0.04 ± 0.01 0.02 ± 0.00 6.4 ± 0.7 9.5 ± 0.8 
 Zov. 2  0.9 0.8 4.9 ± 0.5 5.6 ± 0.5  0.03 ± 0.01 0.04 ± 0.01 4.6 ± 0.5 4.4 ± 0.4 
5 Pliva 1 1.2 0.7 5.4 ± 0.7 4.3 ± 0.7  0.01 ± 0.01 0.03 ± 0.01 6.3 ± 0.9 2.9 ± 0.5 
6 Pliva 1 2.4 2.4 5.0 ± 0.4 5.8 ± 0.4  0.05 ± 0.01 0.04 ± 0.01 11.8 ± 0.9 13.8 ± 1.1 
 Pliva 2 1.8 1.5 1.7 ± 0.3 2.8 ± 0.5  0.17 ± 0.07 0.12 ± 0.04 2.9 ± 0.5 4.2 ± 0.7 
(1) Rm and Rg defined in Equations 7 and 8, respectively. 
(2) Derived from fitting the normalised DPK data to Equations 9 and 10.  
(3) No statistical difference between the values derived from the gravimetric and imaging methods [2-tail paired non-parametric t-test, p>0.05]. 
 
